

PIK3CA gene

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

Normal Function

The *PIK3CA* gene provides instructions for making the p110 alpha (p110 α) protein, which is one piece (subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3K). The p110 α protein is called the catalytic subunit because it performs the action of PI3K, while the other subunit (produced by a different gene) regulates the enzyme's activity.

Like other kinases, PI3K adds a cluster of oxygen and phosphorus atoms (a phosphate group) to other proteins through a process called phosphorylation. PI3K phosphorylates certain signaling molecules, which triggers a series of additional reactions that transmit chemical signals within cells. PI3K signaling is important for many cell activities, including cell growth and division (proliferation), movement (migration) of cells, production of new proteins, transport of materials within cells, and cell survival. Studies suggest that PI3K signaling may be involved in the regulation of several hormones and may play a role in the maturation of fat cells (adipocytes).

Health Conditions Related to Genetic Changes

Bladder cancer

Somatic mutations in the *PIK3CA* gene have been found in some cases of bladder cancer. Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply uncontrollably to form a tumor. Bladder cancer may cause blood in the urine, pain during urination, frequent urination, the feeling of needing to urinate without being able to, or lower back pain.

Bladder cancer is generally divided into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), based on where in the bladder the tumor is located. A *PIK3CA* gene mutation has been found in about half of NMIBC tumors. These mutations change single amino acids in the p110 α protein. The altered p110 α subunit appears to allow PI3K to become overactive. The increased signaling by PI3K likely contributes to uncontrolled cell growth and division and the formation of bladder cancer.

Epidermal nevus

Mutations in the *PIK3CA* gene have been found in up to a quarter of people with a certain type of epidermal nevus (plural: nevi). Specifically, *PIK3CA* gene mutations are associated with some keratinocytic epidermal nevi, which are abnormal skin growths that are composed of skin cells called keratinocytes. *PIK3CA* gene mutations have not been found in other types of epidermal nevi.

The most common *PIK3CA* gene mutation found in epidermal nevi replaces the protein building block (amino acid) glutamic acid with the amino acid glycine at position 545 of the p110 α protein (written as Glu545Gly or E545G). Studies suggest that this mutation causes cells to grow and divide more than normal. The resulting overgrowth of skin cells leads to formation of epidermal nevi. The genetic changes associated with this condition are somatic mutations and are present only in the cells of the nevus.

Despite the involvement of *PIK3CA* gene mutations in many cancers (described above) and the overgrowth of cells caused by changes in this gene, individuals with an epidermal nevus do not appear to have an elevated risk of developing cancer.

Klippel-Trenaunay syndrome

At least five mutations in the *PIK3CA* gene have been found to cause Klippel-Trenaunay syndrome. This condition is characterized by a red birthmark called a port-wine stain, abnormal overgrowth of soft tissues (such as skin and muscles) and bones, and vein malformations. The *PIK3CA* gene mutations associated with this condition arise randomly in one cell during the early stages of development before birth. These changes, which are called somatic mutations, are not inherited. As cells continue to divide during development, cells arising from the first abnormal cell will have the mutation, and other cells will not. This mixture of cells with and without a genetic mutation is known as mosaicism.

The *PIK3CA* gene mutations associated with Klippel-Trenaunay syndrome change single protein building blocks (amino acids) in the p110 α protein. These changes lead to production of an altered p110 α subunit that makes PI3K abnormally active. The altered enzyme triggers unregulated chemical signaling in cells, which allows cells to grow and divide continuously. Increased cell proliferation leads to abnormal growth of the bones, soft tissues, and blood vessels.

Despite the involvement of *PIK3CA* gene mutations in cancer (described below) and the overgrowth of cells caused by changes in this gene, individuals with Klippel-Trenaunay syndrome do not appear to have an elevated risk of developing cancer.

Megalencephaly-capillary malformation syndrome

At least 15 mutations in the *PIK3CA* gene have been found to cause a condition known as megalencephaly-capillary malformation syndrome (MCAP), which is characterized by overgrowth of the brain (megalencephaly) and abnormalities caused by enlargement of small blood vessels in the skin (capillary malformations). The mutations that cause MCAP overlap with those that cause Klippel-Trenaunay syndrome (described above). These mutations are not inherited from a parent; they arise randomly in one cell during

the early stages of development before birth and lead to mosaicism. The presence of the mutation in different tissues helps explain why multiple conditions can be caused by the same gene mutations.

Most *PIK3CA* gene mutations involved in MCAP change single amino acids in the p110 α protein. These mutations lead to the production of an altered p110 α subunit that makes PI3K abnormally active. The resulting unregulated signaling allows cells to grow and divide continuously. Increased cell proliferation in the brain and other tissues and organs leads to the overgrowth characteristic of MCAP.

Despite the involvement of the *PIK3CA* gene mutations in many cancers (described below) and the overgrowth of cells caused by changes in this gene, individuals with MCAP do not appear to have an elevated risk of developing cancer.

Cholangiocarcinoma

MedlinePlus Genetics provides information about Cholangiocarcinoma

Cowden syndrome

MedlinePlus Genetics provides information about Cowden syndrome

Head and neck squamous cell carcinoma

MedlinePlus Genetics provides information about Head and neck squamous cell carcinoma

Lung cancer

MedlinePlus Genetics provides information about Lung cancer

Ovarian cancer

MedlinePlus Genetics provides information about Ovarian cancer

Other disorders

Mutations in the *PIK3CA* gene, including those found in some cancers, have been found to cause several other conditions related to overgrowth of tissues. These conditions include hemimegalencephaly; fibroadipose hyperplasia; and a condition called congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal or spinal abnormalities (CLOVES) syndrome. Hemimegalencephaly is characterized by enlargement of one side of the brain and can cause seizures and intellectual disability. Fibroadipose hyperplasia causes overgrowth of fibrous and fatty (adipose) tissues in various regions of the body, which leads to enlargement of different portions of the body, such as the lower body, an individual arm or leg, or one or more fingers or toes. CLOVES syndrome has multiple features, including an overgrowth of adipose tissue in the abdomen that is often associated with a reddish birthmark on the skin over it, in addition to blood vessel, skin, and bone abnormalities. It is unknown whether individuals

with these disorders have an elevated risk of developing cancer.

As in Klippel-Trenaunay syndrome, MCAP, and epidermal nevus (each described above), the genetic changes involved in these disorders occur early in development and are found in only some of the body's cells. This mosaicism helps explain why different conditions involving different parts of the body can be caused by the same gene mutations. Together, the overgrowth disorders caused by *PIK3CA* gene mutations are known as the *PIK3CA*-related overgrowth spectrum (PROS).

Cancers

Somatic mutations in the *PIK3CA* gene are found in many other types of cancer, including cancer of the ovary, breast, lung, brain, and stomach. These mutations are also involved in cancer of the colon (large intestine) and rectum, which are collectively referred to as colorectal cancer. These mutations change single amino acids in the p110 α protein. Two common mutations occur in the same region and change the amino acid glutamate at position 542 or at position 545 of the p110 α protein to the amino acid lysine (written as Glu542Lys and Glu545Lys, respectively). Two other common mutations occur in another region, changing the amino acid histidine at position 1047 of p110 α to the amino acid arginine or leucine (written as His1047Arg and His1047Leu, respectively).

Cancer-associated *PIK3CA* gene mutations result in production of an altered p110 α subunit that allows PI3K to signal without regulation. The increased signaling can contribute to an uncontrolled proliferation of cells, leading to the development of cancer. However, *PIK3CA* gene mutations may not cause cancer by themselves. Researchers suspect that some cases of cancer likely result from a combination of mutations in *PIK3CA* and mutations in other genes that influence cancer risk.

Other Names for This Gene

- p110-alpha
- phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha
- phosphatidylinositol 3-kinase, catalytic, alpha polypeptide
- phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
- phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha
- phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
- phosphoinositide-3-kinase, catalytic, alpha polypeptide
- PI3-kinase p110 subunit alpha
- PI3K
- PI3K-alpha
- PK3CA_HUMAN
- ptdIns-3-kinase subunit p110-alpha
- serine/threonine protein kinase PIK3CA

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

- Tests of PIK3CA ([https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=5290\[geneid\]](https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=5290[geneid]))

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28PIK3CA%5BTI%5D%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+360+days%22%5Bdp%5D>)

Catalog of Genes and Diseases from OMIM

- PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, ALPHA; PIK3CA (<https://omim.org/entry/171834>)
- CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI (<https://omim.org/entry/612918>)

Gene and Variant Databases

- NCBI Gene (<https://www.ncbi.nlm.nih.gov/gene/5290>)
- ClinVar ([https://www.ncbi.nlm.nih.gov/clinvar?term=PIK3CA\[gene\]](https://www.ncbi.nlm.nih.gov/clinvar?term=PIK3CA[gene]))

References

- Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. *Nature*. 2008 May 29;453(7195):662-6. doi: 10.1038/nature06892. Epub 2008 Apr 30. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/18449193>)
- Hafner C, Lopez-Knowles E, Luis NM, Toll A, Baselga E, Fernandez-Casado A, Hernandez S, Ribe A, Mentzel T, Stoeck R, Hofstaedter F, Landthaler M, Vogt T, Pujol RM, Hartmann A, Real FX. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. *Proc Natl Acad Sci U S A*. 2007 Aug 14;104(33):13450-4. doi: 10.1073/pnas.0705218104. Epub 2007 Aug 2. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/17673550>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1948900/>)
- Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP, Warman ML. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. *Am J Hum Genet*. 2012

Jun8;90(6):1108-15. doi: 10.1016/j.ajhg.2012.05.006. Epub 2012 May 31. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/22658544>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370283/>)

- Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG. Denovo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. *Nat Genet.* 2012 Jun 24;44(8):941-5. doi: 10.1038/ng.2329. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/22729223>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417942/>)
- Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotziou C, Dixon AK, Helliwell T, Rahilly S, Savage DB, Wakelam MJ, Barroso I, Biesecker LG, Semple RK. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. *Nat Genet.* 2012 Jun 24;44(8):928-33. doi: 10.1038/ng.2332. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/22729222>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461408/>)
- Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB, Rahbar R, Spencer SA, Trenor CC 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A, Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. *J Pediatr.* 2015 Apr;166(4):1048-54.e1-5. doi:10.1016/j.jpeds.2014.12.069. Epub 2015 Feb 11. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/25681199>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498659/>)
- Mirzaa G, Graham JM Jr, Keppler-Noreuil K. PIK3CA-Related Overgrowth Spectrum. 2013 Aug 15 [updated 2023 Apr 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews* (R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from <http://www.ncbi.nlm.nih.gov/books/NBK153722/> Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/23946963>)
- Riviere JB, Mirzaa GM, Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggart AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL; Finding of Rare Disease Genes (FORGE) Canada Consortium; Majewski J, Bulman DE, Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nat Genet.* 2012 Jun 24;44(8):934-40. doi:10.1038/ng.2331. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/22729224>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408813/>)

- Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de SaCarvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network; Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell*. 2018 Aug 9;174(4):1033. doi:10.1016/j.cell.2018.07.036. No abstract available. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/30096301>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297116/>)
- Vahidnezhad H, Youssefian L, Uitto J. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). *Exp Dermatol*. 2016 Jan;25(1):17-9. doi: 10.1111/exd.12826. Epub 2015 Oct 13. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/26268729>)
- Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. *Oncogene*. 2008 Sep 18;27(41):5486-96. doi: 10.1038/onc.2008.244. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/18794883>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757120/>)
- Zhao L, Vogt PK. Hot-spot mutations in p110alpha of phosphatidylinositol3-kinase (p13K): differential interactions with the regulatory subunit p85 and with RAS. *Cell Cycle*. 2010 Feb 1;9(3):596-600. doi: 10.4161/cc.9.3.10599. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20009532>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835815/>)

Genomic Location

The *PIK3CA* gene is found on chromosome 3 (<https://medlineplus.gov/genetics/chromosome/3/>).

Last updated February 2, 2021